Initiator Pharma is a Clinical stage pharmaceutical company based in Aarhus. Initiator Pharma is dedicated to developing novel-acting CNS drugs to treat conditions with significant unmet needs. The lead candidate IPED2015 has generated a Proof-of-concept in Phase 2a study as a new treatment for organic erectile dysfunction (ED). It will target the large group of patients suffering from erectile dysfunction and who are resistant to current treatment methods. The other clinical candidate IP2018, is currently in an ongoing Phase 2a study for psychogenic erectile dysfunction.
Established in 2016.